Key points are not available for this paper at this time.
DICUMAROL is of proved value in the prophylaxis and treatment of thromboembolic disease. In recent years it has come into general clinical usage. The narrow margin between a clinically effective prothrombin level and the prothrombin level at which bleeding occurs imposes a certain hazard in treatment. Even with the most careful management of Dicumarol therapy, an unsuspected complication such as an asymptomatic peptic ulcer may result in fatal hemorrhage. The literature attests the seriousness of such bleeding in patients treated with Dicumarol.1 2 3 4In event of hemorrhage it is of the utmost importance to remedy quickly the coagulation defect produced by . . .
Building similarity graph...
Analyzing shared references across papers
Loading...
New England Journal of Medicine
Harvard University
University of Washington Medical Center
Add This Paper to Your Research Feed
Any time a new paper drops it will be there.
Miller et al. (Thu,) studied this question.